The study identifies two new genes, SRRM2 and AKAP11, linked to schizophrenia, with implications for drug development. The research, published in Nature Genetics, highlights the importance of rare protein-truncating variants (PTVs) in understanding the genetic architecture of schizophrenia. The study, conducted on a diverse cohort, emphasizes the need for large patient cohorts to identify PTVs and genes associated with the disorder. The findings suggest a shared risk for schizophrenia and autism in the gene PCLO. The study's inclusion of diverse populations is crucial for developing pharmaceutical agents that can benefit a wider range of individuals.
Para Outro Idioma
do conteúdo original
www.medscape.com
Principais Insights Extraídos De
by Kelli Whitlo... às www.medscape.com 03-23-2023
https://www.medscape.com/viewarticle/990039Perguntas Mais Profundas